'''Igmesine''' ('''JO-1,784''') is a [[sigma receptor]] [[agonist]] ([[IC50|IC<sub>50</sub>]] = 39&nbsp;nM (rat brain)).<ref name="pmid1979628">{{cite journal |vauthors=Roman FJ, Pascaud X, Martin B, Vauché D, Junien JL |title=JO 1784, a potent and selective ligand for rat and mouse brain sigma-sites |journal=The Journal of Pharmacy and Pharmacology |volume=42 |issue=6 |pages=439–40 |date=June 1990 |pmid=1979628 |doi= 10.1111/j.2042-7158.1990.tb06588.x|url=}}</ref><ref name="pmid20438757">{{cite journal | vauthors = Fishback JA, Robson MJ, Xu YT, Matsumoto RR | title = Sigma receptors: potential targets for a new class of antidepressant drug | journal = Pharmacol. Ther. | volume = 127 | issue = 3 | pages = 271–82 | year = 2010 | pmid = 20438757 | pmc = 3993947 | doi = 10.1016/j.pharmthera.2010.04.003 | url = }}</ref> It has [[neuroprotective]] and [[antidepressant]]-like effects in animal studies,<ref name="pmid7498313">{{cite journal |vauthors=O'Neill M, Caldwell M, Earley B, Canney M, O'Halloran A, Kelly J, Leonard BE, Junien JL |title=The sigma receptor ligand JO 1784 (igmesine hydrochloride) is neuroprotective in the gerbil model of global cerebral ischaemia |journal=European Journal of Pharmacology |volume=283 |issue=1-3 |pages=217–25 |date=September 1995 |pmid=7498313 |doi= 10.1016/0014-2999(95)00356-P|url=}}</ref><ref name="pmid11445194">{{cite journal |vauthors=Akunne HC, Zoski KT, Whetzel SZ, Cordon JJ, Brandon RM, Roman F, Pugsley TA |title=Neuropharmacological profile of a selective sigma ligand, igmesine: a potential antidepressant |journal=Neuropharmacology |volume=41 |issue=1 |pages=138–49 |date=July 2001 |pmid=11445194 |doi= 10.1016/S0028-3908(01)00049-1|url=}}</ref> as well as [[nootropic]] effects in models of age-related cognitive decline.<ref name="pmid8891305">{{cite journal |vauthors=Maurice T, Roman FJ, Su TP, Privat A |title=Beneficial effects of sigma agonists on the age-related learning impairment in the senescence-accelerated mouse (SAM) |journal=Brain Research |volume=733 |issue=2 |pages=219–30 |date=September 1996 |pmid=8891305 |doi= 10.1016/0006-8993(96)00565-3|url=}}</ref> In two [[Phases of clinical research#Phase II|phase II]] [[clinical trial]]s, igmesine was found to be effective in the treatment of [[depression (mood)|depression]] and was as active as the comparator [[fluoxetine]].<ref name="pmid20438757" /> However, in a large [[Phases of clinical research#Phase III|phase III]] clinical trial, igmesine failed to show significant effectiveness for depression.<ref name="pmid21375464">{{cite journal | vauthors = Hayashi T, Tsai SY, Mori T, Fujimoto M, Su TP | title = Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders | journal = Expert Opin. Ther. Targets | volume = 15 | issue = 5 | pages = 557–77 | year = 2011 | pmid = 21375464 | pmc = 3076924 | doi = 10.1517/14728222.2011.560837 | url = }}</ref> The drug has not been developed further.<ref name="pmid15547788">{{cite journal |vauthors=Volz HP, Stoll KD |title=Clinical trials with sigma ligands |journal=Pharmacopsychiatry |volume=37 Suppl 3 |issue= |pages=S214–20 |date=November 2004 |pmid=15547788 |doi=10.1055/s-2004-832680 |url=}}</ref>
